Supplementary Figure 10: FACS plots of primary acute myeloid leukemia cells.
From: High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays
FACS plots of two primary AML samples whose growth properties were assessed on the SMR. Fresh primary peripheral blood or bone marrow samples from patients with newly diagnosed AML were subject to erythrocyte lysis and stained with antibodies targeting human CD33 and human CD15, and leukemia cells were enriched by performing FACS for hCD33/hCD15 double-positive cells. Left panel (sample 1): primary peripheral blood sample from a patient with AML with monocytic differentiation and extensive circulating disease. Contemporaneous clinical testing confirmed that this leukemia expressed CD33 and CD15 and demonstrated that it comprised 43% of peripheral blood mononuclear cells, on which this sample was gated. Of note, this specimen was obtained after the patient had received cytoreductive chemotherapy (hydroxyurea) for three days. Right panel (sample 2): primary bone marrow aspirate from a patient with therapy-related AML. Of note, this specimen did not undergo immunophenotyping by the clinical lab, but morphologic analysis suggested that the leukemia comprised a minority of cells in this double-positive population.
